The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Open accessAbstract
Background Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.Methods A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis.Findings When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT.Interpretation A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy.Funding National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our finding that a polygenic risk score has robust associations with incident coronary events is well aligned with previous studies of both primary and secondary prevention populations.16–24”
From Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease (2016) · cites this paper as [22]
In the citing paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
From Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations (2018) · cites this paper as [20]
In the citing paper
“These risk alleles, when aggregated into a polygenic risk score, are predictive of incident coronary events and provide a continuous and quantitative measure of genetic susceptibility.16–24”
From Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease (2016) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
RetractedSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationSever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Cited by
Sorted by citations
Items 301–400 of 704
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 16
Genome-Wide Association Studies and Risk Scores for Coronary Artery Disease: Sex Biases
Byars, S., & Inouye, M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_38 · Cited by 16
Nugent, S., Potvin, O., Cunnane, S. C., Chen, T., & Duchesne, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.580633 · Cited by 16
Statins and Abnormal Liver Function Tests: Is There a Correlation?
Ashraf, J., Khan, M. A., Minhaj, S., Khatti, S., Aarij, K. M., Shehzad, D. M., & Khan, T. M. (2020) · Cureus · doi:10.7759/cureus.10145 · Cited by 15
Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region
Tada, H., Yeo, K. K., Li, J., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.008 · Cited by 15
Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, K. R., & Chait, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101658 · Cited by 18
Sapkota, Y., Liu, Q., Li, N., Bhatt, N. S., Ehrhardt, M. J., Wilson, C. L., Wang, Z., Jefferies, J. L., Zhang, J., Armstrong, G. T., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.04.003 · Cited by 16
Urbut, S., Yeung, M., Khurshid, S., Cho, S. J., Schuermans, A., German, J., Taraszka, K., Paruchuri, K., Fahed, A., Ellinor, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49296-9 · Cited by 16
Christensen, C. L., Helge, J. W., Krasnik, A., Kriegbaum, M., Rasmussen, L. J., Hickson, I. D., Liisberg, K. B., Oxlund, B., Bruun, B., Lau, S. R., et al. (2016) · Scandinavian Journal of Public Health · doi:10.1177/1403494816636304 · Cited by 15
Christiansen, M. K., Larsen, S. B., Nyegaard, M., Neergaard‐Petersen, S., Würtz, M., Grove, E. L., Hvas, A., Jensen, H. K., & Kristensen, S. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.01.090 · Cited by 15
Genetic Risk Score for Coronary Heart Disease: Review
Semaev, S., & Шахтшнейдер, Е. В. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040239 · Cited by 17
Song, H., Koh, Y., Rhee, T., Choi, S.-Y., Kang, S., & Lee, S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.021 · Cited by 16
de Denus, S., Rouleau, J. L., Mann, D. L., Huggins, G. S., Cappola, T. P., Shah, S. H., Keleti, J., Zada, Y. F., Provost, S., Bardhadi, A., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.4 · Cited by 15
Naderian, M., Hamed, M. E., Vaseem, A. A., Norland, K., Dikilitas, O., Teymourzadeh, A., Bailey, K. R., & Kullo, I. J. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004968 · Cited by 20
Tang, J., Sheng, C., Wu, Y. Y., Yan, L. L., & Wu, C. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028200 · Cited by 14
Peng, X.-D., Li, Y.-K., Liu, N., Xia, S., Li, X., Lai, Y., He, L., Sang, C., Dong, J.-Z., & Ma, C.-S. (2024) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.124.013037 · Cited by 14
Long-Term Risk Factor Control After Myocardial Infarction—A Need for Better Prevention Programmes
Osteresch, R., Fach, A., Schmucker, J., Eitel, I., Langer, H. F., Hambrecht, R., & Wienbergen, H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081114 · Cited by 14
Field, P. A., & Vasan, R. S. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1126 · Cited by 14
The role of blood CXCL12 level in prognosis of coronary artery disease: A meta-analysis
Zhang, S., Ding, Y., Feng, F., & Gao, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.938540 · Cited by 13
Leveraging information from genetic risk scores of coronary atherosclerosis
Assimes, T. L., Salfati, E., & Gobbo, L. C. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000400 · Cited by 15
Estimating the heritability of SARS-CoV-2 susceptibility and COVID-19 severity
Brown, K. L., Ramlall, V., Zietz, M., Gisladottir, U., & Tatonetti, N. P. (2024) · Nature Communications · doi:10.1038/s41467-023-44250-7 · Cited by 13
The year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv721 · Cited by 13
Marston, N., Melloni, G. E. M., Gurmu, Y., Bonaca, M. P., Kamanu, F., Roselli, C., Lee, C., Cavallari, I., Giugliano, R. P., Scirica, B. M., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003006 · Cited by 13
Self-citationChristiansen, M. K., Winther, S., Nissen, L., Vilhjálmsson, B. J., Frost, L., Johansen, J. K., Møller, P. L., Schmidt, S. E., Westra, J. S., Holm, N. R., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003298 · Cited by 13
Packard, C. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1003-x · Cited by 13
A genetic risk score predicts recurrent events after myocardial infarction in young adults
Rincon, L. M., Sanmartı́n, M., Salinas, G. L. A., Rodríguez, J. A., Muriel, A., Casas, E., Navarro, M., Carbonell, A., Lázaro, C., Fernández, S., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.08.006 · Cited by 13
Long, C., Li, Z., Jiang, L., Yang, X., Deng, S., Jiang, Y., Zhang, B., & Yue, R. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02747-8 · Cited by 14
Truong, B. M. T., Ruan, Y., Haidermota, S., Patel, A. P., Surakka, I. L., Hornsby, W., Koyama, S., Lee, S., & Natarajan, P. (2024) · Med · doi:10.1016/j.medj.2024.02.015 · Cited by 11
Vernon, S. T., Brentnall, S. J., Currie, D. J., Peng, C., Gray, M. P., Bottà, G., Mujwara, D., Nicholls, S. J., Grieve, S. M., Redfern, J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100672 · Cited by 12
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
Chi, Y., Shi, C., Zhang, X., & Yang, X. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1671-9 · Cited by 12
Genetics, its role in preventing the pandemic of coronary artery disease
Roberts, R., & Fair, J. (2021) · Clinical Cardiology · doi:10.1002/clc.23627 · Cited by 14
Ellis, K. L., Hooper, A. J., Pang, J., Chan, D. C., Burnett, J. R., Bell, D. A., Schultz, C. J., Moses, E. K., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13648 · Cited by 12
Semaev, S., Шахтшнейдер, Е. В., Orlov, P. S., Иванощук, Д. Е., Malyutina, S. K., Гафаров, В. В., Ragino, Y. I., & Voevoda, M. (2019) · Biomolecules · doi:10.3390/biom9110739 · Cited by 14
Li, W., Wang, X., Tian, Y., Xu, L., Zhang, L., Shi, D., Feng, X., Lu, R., & Meng, H. (2019) · Journal of Periodontology · doi:10.1002/jper.19-0135 · Cited by 13
Kessler, T., Schunkert, H., & von Hundelshausen, P. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714352 · Cited by 12
Zhang, Y., Geng, R., Liu, M., Deng, S., Ding, J., Zhong, H., & Tu, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14653 · Cited by 11
Zeljković, A., Mihajlović, M., Vujčić, S., Guzonjić, A., Munjas, J., Stefanović, A., Kotur-Stevuljevic, J., Rizzo, M., Bogavac‐Stanojević, N., Gagić, J., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230510141338 · Cited by 11
Semaev, S., Шахтшнейдер, Е. В., Щербакова, Л. В., Orlov, P. S., Иванощук, Д. Е., Malyutina, S. K., Гафаров, В. В., Voevoda, M. I., & Ragino, Y. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310908 · Cited by 11
Christiansen, M. K., Nyegaard, M., Pedersen, L. N., Larsen, S. B., Würtz, M., Hjort, J., Kristensen, S. D., & Jensen, H. K. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.01.010 · Cited by 13
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 11
Genetic Test, Risk Prediction, and Counseling
Wang, M. H., & Weng, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5717-5_2 · Cited by 11
Statin treatment: can genetics sharpen the focus?
Schunkert, H., & Samani, N. J. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61931-0 · Cited by 11
Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases
Marrero, W. J., Lavieri, M. S., & Sussman, J. B. (2021) · Health Care Management Science · doi:10.1007/s10729-020-09537-x · Cited by 11
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 11
Zhu, Q. M., Hsu, Y.-H. H., Lassen, F. H., MacDonald, B. T., Stead, S. M., Małolepsza, E., Kim, A., Li, T., Mizoguchi, T., Schenone, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-023-05705-1 · Cited by 12
Delabays, B., Trajanoska, K., Walonoski, J., & Mooser, V. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000750 · Cited by 12
Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors
Fabiani, I., Branch, M. E., Cardinale, D. M., Middeldorp, M. E., Sanders, P., Cohen, J. B., Cainzos‐Achirica, M., Jaiswal, S., & Brown, S.-A. N. (2021) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00883-1 · Cited by 11
Lee, S. M., Shivakumar, M., Xiao, B., Jung, S., Nam, Y., Yun, J., Choe, E. K., Jung, Y., Oh, S., Park, J. S., et al. (2023) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2023.03.013 · Cited by 11
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Oni‐Orisan, A., Tuteja, S., Hoffecker, G., Smith, D. M., Castrichini, M., Crews, K. R., Murphy, W. A., Nguyen, N., Huang, Y., Lteif, C., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2957 · Cited by 10
Osmak, G. J., Titov, B. V., Matveeva, N. A., Bashinskaya, V. V., Shakhnovich, R. M., Sukhinina, T. S., Kukava, N. G., Ruda, M. Y., & Favorova, O. O. (2018) · Gene · doi:10.1016/j.gene.2018.01.036 · Cited by 10
Interventions to Reduce Ethnic and Racial Disparities in Dyslipidemia Management
Chang, A. Y., Abou-Arraj, N. E., & Rodriguez, F. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0725-4 · Cited by 12
A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease
Roberts, R., & Chang, C. C. (2020) · Current Genomics · doi:10.2174/1389202921999200630145241 · Cited by 10
Wienbergen, H., Fach, A., Erdmann, J., Katalinic, A., Eisemann, N., Krawitz, P. M., Maj, C., Borisov, O., Munz, M., Nöethen, M. M., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01695-w · Cited by 10
Common Variants for Cardiovascular Disease
Humphries, S. E. (2017) · Circulation · doi:10.1161/circulationaha.117.027798 · Cited by 10
Application of Genomic Data in Translational Medicine During the Big Data Era
Zhang, Y., Yu, J. M., Xie, X., Jiang, F., & Wu, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2901007 · Cited by 10
Mi, N., Liang, Z., Yang, M., Zhao, J., Liang, T. G., Huang, C., Xie, P., Wu, S., He, Q., Sun, Y., et al. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.107942 · Cited by 9
Krohn, J. B., Sprehe, L. K., Sicklinger, F., Kawohl, J., Hess, C., Spieler, A., Dihlmann, S., Eis, L., Gleissner, C. A., Katus, H. A., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322067 · Cited by 9
Mehta, A., Mahtta, D., Gulati, M., Sperling, L. S., Blumenthal, R. S., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0822-6 · Cited by 10
Polygenic risk for coronary artery disease in the Scottish and English population
Yang, C., Starnecker, F., Pang, S., Chen, Z., Güldener, U., Li, L., Heinig, M., & Schunkert, H. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02398-4 · Cited by 10
Myers, R. A., Ortel, T. L., Waldrop, A., Cornwell, M., Newman, J. D., Levy, N., Barrett, T. J., Ruggles, K. V., Sowa, M. A., Davé, S. S., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319759 · Cited by 9
Mekhael, M., Bidaoui, G., Falloon, A., & Pandey, A. C. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.003 · Cited by 10
Pharmacogenomics of Heart Failure: a Systematic Review
Mottet, F., Vardeny, O., & de Denus, S. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0118 · Cited by 10
Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease
Friede, K. A., Li, J. H., & Voora, D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255232 · Cited by 9
Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients
Pihlstrøm, H. K., Mjøen, G., Mucha, S., Franke, A., Jardine, A. G., Fellström, B., Dahle, D. O., Holdaas, H., & Melum, E. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15191 · Cited by 9
Additional value of a combined genetic risk score to standard cardiovascular stratification
Pereira, A., Mendonça, M. I., Borges, S., Sousa, A. C., Freitas, S., Henriques, E., Rodrigues, M. F., Freitas, A. I., Guerra, G., Freitas, C., et al. (2018) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2017-0173 · Cited by 9
Rank concordance of polygenic indices
Muslimova, D., Pereira, R. D., von Hinke, S., van Kippersluis, H., Rietveld, C. A., & Meddens, S. F. W. (2023) · Nature Human Behaviour · doi:10.1038/s41562-023-01544-6 · Cited by 10
Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation
Meiliana, A., Dewi, N. M., & Wijaya, A. (2018) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v10i2.479 · Cited by 11
Jiang, J., Zheng, Q., Han, Y., Qiao, S., Chen, J., Yuan, Z., Yu, B., Ge, L., Jia, J., Gong, Y., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa025 · Cited by 8
Jha, C. K., Mir, R., Banu, S., Elfaki, I., & Chahal, S. M. S. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191015164505 · Cited by 9
Genetics of Coronary Atherosclerosis
Aragam, K. G., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00003-0 · Cited by 9
Self-citationNew Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
Nzeako, T. R., Elendu, C., Echefu, G. C., Olanisa, O., Kiladejo, A., & Bob-Manuel, E. D. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003602 · Cited by 9
Misra, A., Jowell, A. R., Haidermota, S., Perez, E. F., Mahanta, L., O'Brien, K. J., Anna, N., Hao, L., Truong, B. M. T., Aragam, K. G., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.035 · Cited by 9
The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology
Legget, M. E., Cameron, V. A., Poppe, K., Aish, S., Earle, N. J., Choi, Y. C., Bradbury, K. E., Wall, C. R., Stewart, R., Kerr, A., et al. (2021) · Cardiogenetics · doi:10.3390/cardiogenetics11020010 · Cited by 8
Polygenic risk scores in coronary artery disease
Christiansen, M. K., Nyegaard, M., & Jensen, H. K. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001007 · Cited by 9
A multilocus genetic risk score is associated with arterial stiffness in hypertensive patients
Polonis, K., Hoffmann, M., Szyndler, A., Wolf, J., Nowak, R., Becari, C., Laurent, S., Boutouyrie, P., Melander, O., & Narkiewicz, K. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001773 · Cited by 8
Self-citationLow-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Шахтшнейдер, Е. В., Orlov, P. S., Semaev, S., Иванощук, Д. Е., Malyutina, S. K., Гафаров, В. В., Ragino, Y. I., & Voevoda, M. I. (2019) · Biomolecules · doi:10.3390/biom9070290 · Cited by 8
BMPER is upregulated in obesity and seems to have a role in pericardial adipose stem cells
Pérez, L. M., de Lucas, B., & Gálvez, B. G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29829 · Cited by 8
Pharmacogenomics: Overview, Applications, and Recent Developments
Shukla, R. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.93737 · Cited by 11
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
Bauer, A., Zierer, A., Gieger, C., Büyüközkan, M., Müller‐Nurasyid, M., Grallert, H., Meisinger, C., Strauch, K., Prokisch, H., Roden, M., et al. (2021) · Genetic Epidemiology · doi:10.1002/gepi.22389 · Cited by 8
Factores de riesgo cardiovascular
Ros, A. L., Al-Mahdi, E. A. R., Moya, R. R. M., & Gómez, J. L. Z. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.06.011 · Cited by 12
Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
Liu, Y.-W., Huang, M., Hsu, L.-W., Chang, H., Lee, C., Lee, C., Chen, D.-P., Li, Y., Chao, T., Su, P., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103082 · Cited by 10
Xie, J., Feng, Y., Newby, D., Zheng, B., Feng, Q., Prats‐Uribe, A., Li, C., Wareham, N. J., Paredes, R., & Prieto‐Alhambra, D. (2023) · Nature Communications · doi:10.1038/s41467-023-40310-0 · Cited by 8
Messas, N., Dubé, M., & Tardif, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0679-5 · Cited by 8
How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention
Benes, L. B., Brandt, D. J., Brandt, E. J., & Davidson, M. H. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1079-3 · Cited by 8
Ruttmann, E., Abfalterer, H., Dietl, M., Wagner, J. F., Kilo, J., Grimm, M. F., Bates, K., Fritz, J., & Ulmer, H. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz333 · Cited by 8
Genetic risk scores in lipid disorders
Wierzbicki, A. S., & Reynolds, T. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000623 · Cited by 8
A Less than Provocative Approach for the Primary Prevention of CAD
Roberts, R., & Fair, J. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10144-6 · Cited by 8
Dallali, H., Hechmi, M., Morjane, I., Elouej, S., Jmel, H., Halima, Y. B., Abid, A., Bahlous, A. H. S., Barakat, A., Jamoussi, H., et al. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00794-0 · Cited by 8
Reducing Cardiovascular Risk Using Genomic Information in the Era of Precision Medicine
Natarajan, P., & O’Donnell, C. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021765 · Cited by 8
Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery DiseasePreprint
Muse, E. D., Wineinger, N. E., Schrader, B., Molparia, B., Spencer, E. G., Bodian, D. L., Torkamani, A., & Topol, E. J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/101519 · Cited by 8
Interpreting Alzheimer disease polygenic scores
Tan, C. H., & Desikan, R. S. (2018) · Annals of Neurology · doi:10.1002/ana.25164 · Cited by 8
Sun, Q., Rowland, B., Chen, J. C., Mikhaylova, A. V., Avery, C. L., Peters, U., Lundin, J. I., Matise, T. C., Buyske, S. G., Tao, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.06.511219 · Cited by 8
Dimmeler, S., Ferri, L. D. A. F., Nioi, P., O’Donnell, C. J., Damy, T., Gómez‐Outes, A., Giacca, M., Guo, W., Kavousi, M., Kupatt, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf041 · Cited by 7
Zhao, R., Xian, W., Ma, Y., Napolioni, V., Lau, W. C., Tian, X.-L., Guen, Y. L., Franke, A., & Huang, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02669-w · Cited by 7
Kim, J., Kim, D., Kim, D., Park, B., Kang, T. S., Lim, S., Lee, S. Y., Chung, Y. H., Lee, M., Yang, P., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037727 · Cited by 7
Lumkul, L., Wongyikul, P., Kulalert, P., Sompornrattanaphan, M., Lao‐Araya, M., Chuamanochan, M., Nochaiwong, S., & Phinyo, P. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2023.100816 · Cited by 7
Metadata
- Authors
- Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., Poulter, N. R., Sever, P. S., Ridker, P. M., Braunwald, E., Melander, O., Kathiresan, S., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Washington University in St. Louis (US)
- Broad Institute (US)
- Queen Mary University of London (GB)
- Quest Diagnostics (United States) (US)
- Pfizer (United States) (US)
- Imperial College London (GB)
- Lund University (SE)
- Corresponding author
- Mega, Jessica L
- Stitziel, Nathan O
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 385
- Issue
- 9984
- Pages
- 2264-2271
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4608367
- OpenAlex
- W2171705978
- Cited by
- 704
- References
- 46
- Citations by year
- 2026: 40 · 2025: 48 · 2024: 51 · 2023: 69 · 2022: 78 · 2021: 83 · 2020: 78 · 2019: 59 · 2018: 62 · 2017: 53 · 2016: 57 · 2015: 25
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) (RC1 HL099634)
- NIH and the NHLBI (grant K08 HL114642)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- coronary artery disease, polygenic risk score, genetic variants, statin therapy, primary prevention, secondary prevention, number needed to treat, risk stratification, JUPITER trial, ASCOT trial, CARE trial, PROVE IT-TIMI 22, recurrent cardiovascular events, Malmö Diet and Cancer Study, cardiovascular risk prediction, treatment benefit stratification, LDL cholesterol lowering
- MeSH terms
- Coronary Disease, Humans, Primary Prevention, Recurrence, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention, Numbers Needed To Treat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
